Therapy News and Research

RSS

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Pfizer Inc. announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC).

24 Aug 2010

FDA OOPD awards Soligenix $1.2M for orBec Phase 3 study in acute gastrointestinal Graft-versus-Host-Disease

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) pursuant to its Orphan Products Development (OPD) Program.

24 Aug 2010

SEB opens new state-of-the-art laboratory operation, R&D facility

Cryo-Cell International, Inc., one of the largest and most established leaders in stem cell innovation today announced that S-Evans Biosciences, the Company's exclusive Célle menstrual stem cell technology license partner in China has opened a new state-of-the-art laboratory operation and research & development facility located in a Hi-Tech park designated to become an epicenter for stem cell and genomics R&D; cellular therapies and stem cell cryopreservation services.

23 Aug 2010

Multidisciplinary approach to treat neck and back pain caused by accidents, injuries

Advanced Spine and Headache Center is pleased to announce their expansion into a multidisciplinary approach for the treatment of neck and back pain caused by an auto accident, sports injury, or work related injury. "Our main objective was to integrate physical medicine, chiropractic, physical and massage therapy, and family medicine under one location," said founder Dr. Alex Meltser.

23 Aug 2010

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

Genzyme Corporation announced today that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journal's website and are available to subscribers.

23 Aug 2010

InSite Vision initiates Phase 1/2 clinical trial of ISV-303

InSite Vision Incorporated, a company developing novel ophthalmic therapeutics, today announced the initiation of a Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain and inflammation associated with ocular surgery. ISV-303 combines a low dose of the non-steroidal anti-inflammatory bromfenac with InSite Vision's proprietary DuraSite technology.

23 Aug 2010

First Edition: Aug. 23, 2010

Today's headlines include news about developments related to the nation's medical privacy rules and the power struggle surrounding implementation regulations for a key section of the new health law.

23 Aug 2010

Epicept receives refusal to file letter on new drug application

EpiCept Corporation today announced that it received a refusal to file letter from the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Ceplene(histamine dihydrochloride).

23 Aug 2010

New antisense drugs may help treat accidental infections: Study

New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure-suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.

23 Aug 2010

Scientific findings provide new information on prostate cancer care

A new analysis has found that short-term and long-term costs of prostate cancer care vary considerably based on which treatment strategy a man initially receives. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study finds that treatments that may be less expensive in the short-term may have higher long-term costs.

23 Aug 2010

Stanford Hospital installs high-definition monitors to enhance patient care

When a patient checks in to Stanford Hospital from now on, the room wall will have an extra special something. Most hospitals have had televisions in patient rooms for decades. But few now have what Stanford offers its patients on new, 26-inch high definition monitors

21 Aug 2010

NHS Stop Smoking Services helps 373,954 people to quit smoking during 2009-10

NHS Stop Smoking Services helped 373,954 people to quit smoking during 2009-10 - a higher number than ever before.

21 Aug 2010

US oncology announces its contributions in development of 42 novel cancer therapies

US Oncology, Inc., the nation's leading integrated oncology company, announced today that in less than two decades it has played a role in the development of 42 novel cancer therapies approved by the US Food and Drug Administration.

21 Aug 2010

Melanoma Research Alliance announces grant to support six research programs

The Melanoma Research Alliance today announced $5.2 million in grants to support six multidisciplinary teams pursuing innovative, translational research approaches designed to benefit melanoma patients.

21 Aug 2010

WHO calls upon countries to be alert to antimicrobial resistance

Antimicrobial resistance (AMR) - the ability of micro-organisms to find ways to evade the action of the drugs used to cure the infections they cause - is increasingly recognised as a global public health issue which could hamper the control of many infectious diseases. Some bacteria have developed mechanisms which render them resistant to many of the antibiotics normally used for their treatment (multi-drug resistant bacteria), so pose particular difficulties, as there may be few or no alternative options for therapy.

21 Aug 2010

Low testosterone levels to blame for low libido, fatigue and weight gain

While most frequently associated with women's health, age-related hormone changes, often dubbed menopause, can occur in men as well, causing symptoms of fatigue, mood swings, decreased desire for sex, hair loss, lack of concentration and weight gain. Experts estimate that more than 5 million men are affected, yet worry the number may be considerably higher since symptoms are frequently ignored.

21 Aug 2010

Impax confirms initiation of challenge of patents listed by MSP Singapore for VYTORIN

Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by MSP Singapore Co. LLC in connection with VYTORIN® (ezetimibe/simvastatin), 10 mg/80 mg.

21 Aug 2010

Study finds genetic change in chromosome 4 causes FSHD

The Muscular Dystrophy Association today heralds a landmark muscular dystrophy advance by an international study team of scientists and physicians from the Netherlands, United States, France and Spain. Led by MDA-grantee Silvère van der Maarel, Ph.D., at Leiden University Medical Center in the Netherlands, the collaborative study of more than 2,300 people found that two distinct genetic changes on chromosome 4 must be present to cause facioscapulohumeral muscular dystrophy (FSHD).

21 Aug 2010

Combination of 2 FDA approved drugs eliminate HIV infection

Researchers at the University of Minnesota Academic Health Center have identified two drugs that, when combined, may serve as an effective treatment for HIV.

21 Aug 2010

ETC Biomedical Systems receives FDA 510-k clearance for computer hyperbaric oxygen control system

Environmental Tectonics Corporation's Biomedical Systems, a worldwide leader in the development, manufacture of computerized monoplace hyperbaric chambers, today confirmed that it has received FDA 510-k clearance for O.S.C.A.R. ™. O.S.C.A.R. ™ is an acronym for "Operating System for Control And Recording." This computerized system is configured as a stand–alone unit that will operate, control and record whole-body hyperbaric oxygen therapy treatments.

21 Aug 2010

Therapy News and Research

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

FDA OOPD awards Soligenix $1.2M for orBec Phase 3 study in acute gastrointestinal Graft-versus-Host-Disease

SEB opens new state-of-the-art laboratory operation, R&D facility

Multidisciplinary approach to treat neck and back pain caused by accidents, injuries

Genzyme announces publication of phase 2 clinical trial results of eliglustat tartrate for Gaucher disease

InSite Vision initiates Phase 1/2 clinical trial of ISV-303

First Edition: Aug. 23, 2010

Epicept receives refusal to file letter on new drug application

New antisense drugs may help treat accidental infections: Study

Scientific findings provide new information on prostate cancer care

Stanford Hospital installs high-definition monitors to enhance patient care

NHS Stop Smoking Services helps 373,954 people to quit smoking during 2009-10

US oncology announces its contributions in development of 42 novel cancer therapies

Melanoma Research Alliance announces grant to support six research programs

WHO calls upon countries to be alert to antimicrobial resistance

Low testosterone levels to blame for low libido, fatigue and weight gain

Impax confirms initiation of challenge of patents listed by MSP Singapore for VYTORIN

Study finds genetic change in chromosome 4 causes FSHD

Combination of 2 FDA approved drugs eliminate HIV infection

ETC Biomedical Systems receives FDA 510-k clearance for computer hyperbaric oxygen control system

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News